Why has there been so little progress on Alzheimer's disease?

Why has there been so little progress on Alzheimer's disease? delivers a sweeping critique, scoring 316 points and 201 comments. It challenges the efficacy of $1.2 billion in annual global research funding, highlighting that only 5% of drugs tested reach approval. This piece outperforms #2 in engagement, offering a more comprehensive analysis than typical scientific critiques, with a warm yet authoritative tone that resonates.